Evidence map›Paper›PMID 32931317›Full record

ArticleAIDS patient care and STDs2020

Exploring the Engagement of Racial and Ethnic Minorities in HIV Treatment and Vaccine Clinical Trials: A Scoping Review of Literature and Implications for Future Research.

Sarah Bauerle Bass, Paul D'Avanzo, Mohammed Alhajji, Nicole Ventriglia, Aurora Trainor, Laurie Maurer, Rebecca Eisenberg, Omar Martinez

Abstract readScoping Review
In one paragraph

Article in AIDS patient care and STDs, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sarah Bauerle BassRisk Communication Laboratory, Department of Social and Behavioral Sciences, Temple University College of Public Health, Philadelphia, Pennsylvania, USA.
Paul D'AvanzoRisk Communication Laboratory, Department of Social and Behavioral Sciences, Temple University College of Public Health, Philadelphia, Pennsylvania, USA.
Mohammed AlhajjiRisk Communication Laboratory, Department of Social and Behavioral Sciences, Temple University College of Public Health, Philadelphia, Pennsylvania, USA.
Nicole VentrigliaFox Chase Cancer Center, Risk Assessment Program, Philadelphia, Pennsylvania, USA.
Aurora TrainorRisk Communication Laboratory, Department of Social and Behavioral Sciences, Temple University College of Public Health, Philadelphia, Pennsylvania, USA.
Laurie MaurerTennessee Department of Health, HIV/STD/Viral Hepatitis Section, Nashville, Tennessee, USA.
Rebecca EisenbergBoston Medical Center, Boston, Massachusetts, USA.
Omar MartinezSchool of Social Work, Temple University College of Public Health, Philadelphia, Pennsylvania, USA.

Funding

NCHHSTP CDC HHS U01 PS005124
6 · The paper itself

Abstract

HIV disproportionately impacts US racial and ethnic minorities but they participate in treatment and vaccine clinical trials at a lower rate than whites. To summarize barriers and facilitators to this participation we conducted a scoping review of the literature guided by the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guidelines. Studies published from January 2007 and September 2019 were reviewed. Thirty-one articles were identified from an initial pool of 325 records using three coders. All records were then assessed for barriers and facilitators and summarized. Results indicate that while racial and ethnic minority participation in these trials has increased over the past 10 years, rates still do not proportionately reflect their burden of HIV infection. While many of the barriers mirror those found in other disease clinical trials (e.g., cancer), HIV stigma is a unique and important barrier to participating in HIV clinical trials. Recommendations to improve recruitment and retention of racial and ethnic minorities include training health care providers on the importance of recruiting diverse participants, creating interdisciplinary research teams that better represent who is being recruited, and providing culturally competent trial designs. Despite the knowledge of how to better recruit racial and ethnic minorities, few interventions have been documented using these strategies. Based on the findings of this review, we recommend that future clinical trials engage community stakeholders in all stages of the research process through community-based participatory research approaches and promote culturally and linguistically appropriate recruitment and retention strategies for marginalized populations overly impacted by HIV.

Indexed as

Clinical Trials as TopicEthnicityMinority GroupsHIV InfectionsHumansPatient ParticipationPatient SelectionRacial GroupsVaccinesVaccinesbarriers to participationethnic and racial minoritiesHIV clinical trialsscoping review

Identifiers

PMID32931317
PMCPMC10722429

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.